Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

2 treatments under study, led by Human Papillomavirus Quadrivalent Types 6 11 16 And 18 Vaccine Recombinant

Related Conditions

Often studied with 8 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

1Total
Not Applicable (1)

Trial Status

Completed1
Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT06237010Completed

Impact of COVID-19 on Occupational Dermato-allergology Consultations of Health Peronnel

NCT06650956Not ApplicableRecruiting

Integration to Improve Adolescent Health and HPV Vaccination in Laos

Showing all 2 trials

Research Network

Common Treatments

  • Human Papillomavirus Quadrivalent Types 6 11 16 And 18 Vaccine Recombinant1
  • Integrated Hpv And Srh Service Package1

Active Sponsors

  • Centre Hospitalier Intercommunal Creteil1
  • Health Sciences University, Laos1
  • Gavi, The Vaccine Alliance1
  • Health Poverty Action1

Top Investigators

Related Conditions

  • Dermatoses1
  • Healthy1
  • Adolescents1
  • Integrated Communityhealth Systems1
  • Attitude1

Activity Timeline